Iovance biotherapeutics, inc. (IOVA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows from Operating Activities
Net loss

-197,600

-123,580

-92,064

-52,894

-27,660

-12,035

-25,382

-3,307

-25,694

-1,607

-15

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

24,277

20,027

11,968

18,904

8,523

3,814

-

-

-

-

-

Noncash lease expense

6,954

-

-

-

-

-

-

-

-

-

-

Amortization of premiums on investments

-3,421

-1,332

19

-74

0

0

-

-

-

0

0

Depreciation and amortization

1,169

956

952

978

999

88

7

6

2

58

1

Gain on settlement of dispute

336

-

-

-

-

-

-

-

-

-

-

Loss on disposal of assets

-16

-9

-

0

-

-

-

-

-

-

-

Impairment of intangible asset

-

-

-

-

-

-

-

0

160

0

0

Fair value of vested stock options

-

-

-

-

-

-

747

2,528

1,793

114

0

Fair value of derivative liability recorded upon issuance of warrants

-

-

-

-

-

-

-

-

2,563

0

0

Amortization of discount on convertible notes

-

-

-

-

-

-

-

-497

5,000

-

-

Private placement costs

-

-

-

-

-

-

-

515

920

563

0

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

8,635

-1,596

-229

0

Common stock issued to officer for services

-

-

-

-

-

-

-

0

8,010

0

0

Common stock issued for services

-

-

-

-

-

-

274

800

498

0

0

Common stock issued to induce conversion of warrants

-

-

-

-

-

-

-

0

-

-

-

Common stock issued to induce exchange transaction

-

-

-

-

-

-

2,296

875

-

-

-

Common stock issued for Lion transaction

-

-

-

-

-

-

16,656

0

-

-

-

Derivative liability recorded upon issuance of convertible notes and warrants

-

-

-

-

-

-

-

0

5,535

0

0

Derivative liability recorded as offering cost

-

-

-

-

-

-

-

697

642

0

0

Common stock issued to directors

-

-

-

-

-

-

-2,003

0

0

217

0

Fair value of common stock and warrants accounted for as financing costs

-

-

-

-

-

-

-

0

-

-

-

Vesting of restricted shares issued for services

-

-

-

-

-

-

-

0

-

-

-

Common stock issued with note payable reflected as financing cost

-

-

-

-

-

-

-

-

0

-

-

Fair value of common stock transferred to officer and director

-

-

-

-

-

-

-

0

1,742

0

0

Write off of advances to related party

-

-

-

-

-

-

-

0

50

0

0

Changes in assets and liabilities:
Prepaid expenses, other assets, and long-term assets

3,278

2,065

4,508

2,765

211

-108

164

-22

-21

-

-

Operating lease liabilities (Right-of-use assets)

-6,148

-

-

-

-

-

-

-

-

-

-

Accounts payable

12,706

1,507

369

-250

-290

-

-

-

159

-

-

Accrued expenses and other liabilities

6,728

3,229

4,555

3,433

258

-608

-

-

70

-

-

Other assets

-

-

-

-

0

-

-

-

-

0

0

Deposit

-

-

-

-

-

-

-

-

-

-4

0

Accounts payable, accrued expenses and interest and penalty

-

-

-

-

-

-

-

2,580

-

30

-0

Prepaid expenses

-

-

-

-

-

-

-

-

-

-3

0

Accounts payable and accrued expenses

-

-

-

-

-

-

-98

1,875

-

-

-

Accrued interest and penalty

-

-

-

-

-

-

-

-

151

-

-

Net cash used in operating activities

-158,900

-101,249

-78,709

-32,668

-18,381

-8,633

-3,661

-2,241

-6,189

-620

-14

Cash Flows from Investing Activities
Maturities of short-term investments

514,601

41,000

59,705

120,664

70,600

0

0

-

-

-

-

Increase in money market funds

-

-

-

-

-

-

0

-

-

-

-

Purchase of short-term investments

417,659

426,081

-

110,249

140,665

0

0

-

-

-

-

Purchase of property and equipment

6,917

1,198

1,028

1,521

1,143

1,592

13

0

31

0

0

Advances to related party

-

-

-

-

-

-

-

0

50

0

0

Net cash provided by investing activities

90,025

-386,279

58,677

8,894

-71,208

-1,592

-13

0

-81

0

0

Tax payments related to shares withheld for vested restricted stock awards

312

223

1,252

642

0

0

-

-

-

-

-

Proceeds from the issuance of common stock upon exercise of warrants

-

15,754

662

1,235

9,705

3,222

0

-

-

-

-

Proceeds from the issuance of common stock upon exercise of options

6,443

9,959

5,616

626

255

0

0

-

-

-

-

Proceeds from the issuance of secured promissory notes

-

-

-

-

-

-

-

1,481

0

-

-

Proceeds from the issuance of common stock, net

-

-

-

95,685

68,307

32,240

7,126

250

873

1,910

0

Proceeds from the issuance of preferred stock and common stock, net

-

398,817

53,662

-

-

-

15,909

0

-

-

-

Proceeds from the issuance of convertible notes, net

-

-

-

-

-

-

311

0

4,615

0

0

Due to director

-

-

-

-

-

-

-

0

0

-4

19

Net cash provided by / (used in) financing activities

6,131

424,307

58,688

96,904

78,267

35,462

23,346

1,731

5,488

1,905

19

Net increase / (decrease) in cash, cash equivalents and restricted cash

-62,733

-63,221

38,656

73,130

-11,322

25,237

19,672

-510

-782

1,284

5

Supplemental disclosure of cash flow information:
Cash paid for income taxes

-

-

-

0

0

0

-

-

-

-

-

Interest paid

-

-

-

0

0

0

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Net unrealized gain (loss) on short-term investments

262

-42

-29

-19

48

0

0

-

-

-

-

Acquisitions of property and equipment included in accounts payable and accrued expenses

122

-

-

155

0

0

-

-

-

-

-

Offering costs under accounts payable and accrued expenses

-

-

-

49,454

-

-

-

-

-

-

-

Deemed dividend related to a beneficial conversion feature

-

-

-

-

0

0

-

-

-

-

-

Conversion of convertible preferred stock to common stock

2

1

1

3

0

0

-

-

-

-

-

Proceeds from convertible notes held in escrow

-

-

-

-

-

-

-

-

0

-

-

Forgiveness of debt by director, treated as contribution of capital

-

-

-

-

-

-

-

0

0

18

0

Common stock issued upon conversion of convertible notes

-

-

-

-

-

-

6,793

0

-

-

-

Fair value of common stock issued with notes payable recorded as a note discount

-

-

-

-

-

-

-

497

-

-

-

Settlement of accounts payable through issuance of common stock

-

-

-

-

-

-

-

0

-

-

-

Common stock issued upon conversion of accrued interest and penalty

-

-

-

-

-

-

2,475

0

-

-

-